Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 Monotherapy and Combination Therapy in Advanced Hepatocellular Carcinoma
NCT07227012Phase 2Recruiting
- Sponsor
- Pfizer
- Start
- Dec 2025
- Primary completion
- Oct 2027
- Modality
- Bispecific Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of PF-08634404 in hepatocellular carcinoma (HCC), sponsored by Pfizer. Started Dec 2025; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07227012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07227012.